Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model
NCT05340309Phase 2Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab + rHuPH20 in non-small cell lung cancer (NSCLC), sponsored by University of Southern California. Started Dec 2022; status: active, not recruiting.
02
Drugs
atezolizumab + rHuPH20
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05340309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340309.